Composition of solifenacin or salt thereof for use in solid formulation
A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with time. The composition for a solid pharmaceutical preparation of solifenacin or a salt thereof contains solifenacin or its salt each in a crystalline from, and the content provided are: a process for producing the composition; and a medicinal composition for solid pharmaceutical preparations which contains solifenacin and an amorphization inhibitor.
1. A pharmaceutical composition of solifenacin or a salt thereof for use in a solid formulation, the composition containing crystalline and amorphous solifenacin or a crystalline and amorphous salt thereof, together with an inhibitor of an amorphous preparation, wherein the inhibitor of an amorphous preparation is a substance having an ethylene oxide chain and wherein a composition wherein the crystalline and amorphous solifenacin or a crystalline and amorphous salt thereof is not in contact with or in mixture with the inhibitor of an amorphous preparation is excluded.
2. The pharmaceutical composition according to claim 1 , wherein the substance having an ethylene oxide chain is polyethylene glycol, polyethylene oxide, polyoxyethylene polyoxypropylene block copolymer, polyoxyethylene hardened castor oil, or polyethylene glycol fatty acid ester.
3. A pharmaceutical composition according to claim 2 , wherein the substance having an ethylene oxide chain is polyethylene glycol.